Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain mapping

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Brain mapping. Displaying page 1 of 1.
    EudraCT Number: 2007-001206-24 Sponsor Protocol Number: 16901 Start Date*: 2007-07-31
    Sponsor Name:UMCG
    Full Title: Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004474-15 Sponsor Protocol Number: PETFLUTEMETAMOL-FDG/BBRC2015 Start Date*: 2016-03-14
    Sponsor Name:BarcelonaBeta Brain Research Center
    Full Title: Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled in the ALFA project
    Medical condition: Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10036654 Prevention LLT
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020338-25 Sponsor Protocol Number: WA25046 Start Date*: 2010-11-02
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis
    Medical condition: Primary Progressive Multiple Sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000797-30 Sponsor Protocol Number: SPI-IIT-002 Start Date*: 2013-10-08
    Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital
    Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation
    Medical condition: Paroxysmal and persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10071667 Persistent atrial fibrillation LLT
    18.1 100000004849 10066664 Recurrent symptomatic atrial fibrillation LLT
    18.1 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-020315-36 Sponsor Protocol Number: WA21093 Start Date*: 2011-10-18
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-003284-19 Sponsor Protocol Number: CTU/2013/073 Start Date*: 2017-01-24
    Sponsor Name:University College London
    Full Title: DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease.
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-020337-99 Sponsor Protocol Number: WA21092 Start Date*: 2011-10-20
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) LV (Completed) HU (Completed) FI (Completed) DE (Completed) BE (Completed) SK (Completed) AT (Completed) NL (Ongoing) LT (Completed) EE (Completed) PT (Completed) BG (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018566-23 Sponsor Protocol Number: EORTCprotocol08092 Start Date*: 2011-05-17
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung group study.
    Medical condition: Non Small Cell Lung Cancer patients non progressive after first line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended) SI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001088-26 Sponsor Protocol Number: MN42928 Start Date*: 2021-12-21
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004215-30 Sponsor Protocol Number: BRD/05/155 Start Date*: 2006-02-24
    Sponsor Name:Joint Sponsorship: University College London (UCL) & University College London Hospitals (UCLH)
    Full Title: Imaging the neural correlates of cholinergic and behaviour driven rehabilitation in patients with Wernicke’s aphasia: a double-blinded, cross-over, randomised controlled trial.
    Medical condition: Wernicke's aphasia caused by a stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004405-64 Sponsor Protocol Number: MT-2-03 Start Date*: 2019-03-07
    Sponsor Name:Minoryx Therapeutics BE, SA
    Full Title: A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia
    Medical condition: Friedreich’s Ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003447-34 Sponsor Protocol Number: REQ-0000020479 Start Date*: 2019-04-03
    Sponsor Name:Hellenic Genitourinary Cancer Group (HGUCG)
    Full Title: Nivolumab plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC) not undergoing cystectomy: a phase II, randomized study
    Medical condition: muscle-invasive bladder cancer (MIBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002219-69 Sponsor Protocol Number: CHUBX2019/49 Start Date*: 2021-07-19
    Sponsor Name:CHU de Bordeaux
    Full Title: Long-term iron chelation in the prevention of secondary degeneration after cerebral infarction
    Medical condition: Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003465-38 Sponsor Protocol Number: MS-tolDC_Phase2-RESTORE Start Date*: 2023-05-08
    Sponsor Name:Antwerp University Hospital [...]
    1. Antwerp University Hospital
    2. Hospital Universitari Germans Trias i Pujol
    Full Title: A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for multiple sclerosis
    Medical condition: Diagnosis of multiple sclerosis, according to the most recent diagnostic criteria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004246-20 Sponsor Protocol Number: 20810 Start Date*: 2018-03-06
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor LOXO-1...
    Medical condition: NTRK fusion cancers previously treated with a TRK inhibitor
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049516 Malignant tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IE (Completed) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001314-19 Sponsor Protocol Number: VO659-CT01 Start Date*: 2023-04-25
    Sponsor Name:VICO Therapeutics B.V.
    Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp...
    Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10057660 Spinocerebellar ataxia LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 14:11:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA